参考文献/References:
[1]Li X,Li D,Wu JC,et al.Precision dosing of warfarin: open questions and strategies[J].Pharmacogenomics J,2019,19(3):219-229.[2]Catterall F,Ames PR,Isles C.Warfarin in patients with mechanical heart valves[J].BMJ,2020,371:m3956.[3]Bai Y,Deng H,Shantsila A,et al.Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation:Systematic Review and Meta-Analysis[J].Stroke,2017,48(4):970-976.[4]Tan CSS,Lee SWH.Warfarin and food,herbal or dietary supplement interactions:A systematic review[J].Br J Clin Pharmacol,2021,87(2):352-374.[5]Ruff CT.Pharmacogenetics of Warfarin Therapy[J].Clin Chem,2018,64(11):1558-1559.[6]Arwood MJ,Deng J,Drozda K,et al.Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting:A proposal for a new pharmacogenetic dosing approach[J].Clin Pharmacol Ther,2017,101(5):675-683.[7]Gage BF,Bass AR,Lin H,et al.Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty:The GIFT Randomized Clinical Trial[J].JAMA,2017,318(12):1115-1124.[8]Budnitz DS,Lovegrove MC,Shehab N,et al.Emergency hospitalizations for adverse drug events in older Americans[J].N Engl J Med,2011,365(21):2002-2012.[9]Asiimwe IG,Zhang EJ,Osanlou R,et al.Warfarin dosing algorithms:A systematic review[J].Br J Clin Pharmacol,2021,87(4):1717-1729.[10]Kaye JB,Schultz LE,Steiner HE,et al.Warfarin Pharmacogenomics in Diverse Populations[J].Pharmacotherapy,2017,37(9):1150-1163.[11]Tang W,Shi QP,Ding F,et al.Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage:A novel systematic review and meta-analysis of 53 studies[J].Int J Clin Pharmacol Ther,2017,55(4):304-321.[12]Waring RH.Cytochrome P450:genotype to phenotype[J].Xenobiotica,2020,50(1):9-18.[13]Takeuchi M,Kobayashi T,Biss T,et al.CYP2C9,VKORC1,and CYP4F2 polymorphisms and pediatric warfarin maintenance dose:a systematic review and meta-analysis[J].Pharmacogenomics J,2020,20(2):306-319.[14]Dai DP,Xu RA,Hu LM,et al.CYP2C9 polymorphism analysis in Han Chinese populations:building the largest allele frequency database[J].Pharmacogenomics J,2014,14(1):85-92.[15]Chen H,Dai DP,Zhou S,et al.An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62[J].Chem Biol Interact,2020,327:109168.[16]Nizamuddin S,Dubey S,Singh S,et al.CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations[J].Pharmgenomics Pers Med,2021,14:135-147.[17]Johnson JA,Caudle KE,Gong L,et al.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing:2017 Update[J].Clin Pharmacol Ther,2017,102(3):397-404.[18]Kumondai M,Ito A,Gutiérrez Rico EM,et al.Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals[J].J Pers Med,2021,11(2):94.[19]Sridharan K,Sivaramakrishnan G.A network meta-analysis of CYP2C9,CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional[J].J Clin Pharm Ther,2021,46(3):640-648.[20]Lindh JD,Holm L,Andersson ML,et al.Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis[J].Eur J Clin Pharmacol,2009,65(4):365-375.[21]Asiimwe IG,Zhang EJ,Osanlou R,et al.Genetic Factors Influencing Warfarin Dose in Black-African Patients:A Systematic Review and Meta-Analysis[J].Clin Pharmacol Ther,2020,107(6):1420-1433.[22]Lindley KJ,Limdi NA,Cavallari LH,et al.Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles[J].Clin Pharmacol Ther,2022,111(4):950-955.[23]Cavallari LH,Langaee TY,Momary KM,et al.Genetic and clinical predictors of warfarin dose requirements in African Americans[J].Clin Pharmacol Ther,2010,87(4):459-464.[24]O’Brien TJ,Kidd RS,Richard CA,et al.First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele[J].Clin Chim Acta,2013,424:73-75.[25]Kim HS,Lee SS,Oh M,et al.Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement[J].Pharmacogenet Genomics,2009,19(2):103-112.[26]Lee YM,Eggen J,Soni V,et al.Warfarin dose requirements in a patient with the CYP2C9*14 allele[J].Pharmacogenomics,2014,15(7):909-914.[27]Ciccacci C,Falconi M,Paolillo N,et al.Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient[J].Pharmacogenet Genomics,2011,21(6):344-346.[28]Ji Y,Chen S,Zhao L,et al.In vitro assessment of 39 CYP2C9 variants found in the Chinese population on the metabolism of the model substrate fluoxetine and a summary of their effects on other substrates[J].J Clin Pharm Ther,2015,40(3):320-327.[29]Hu GX,Pan PP,Wang ZS,et al.In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population[J].Drug Metab Dispos,2015,43(4):561-569.[30]Wang D,Dai DP,Wu H,et al.Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation[J].Pharmacogenomics,2020,21(14):1021-1031.[31]Wang F,Guo J,Zhang A.Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population:A Meta-analysis of Randomized Controlled Trials[J].J Cardiovasc Pharmacol,2019,73(3):127-135.